Close

Gilead Sciences (GILD) Receives FDA Approval for Epclusa as HCV Treatment in All Genotypes

June 28, 2016 12:35 PM EDT Send to a Friend
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has approved Epclusa (sofosbuvir 400 mg/velpatasvir ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login